Impact of imatinib on reducing the painful crisis in patients with sickle cell disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20131106015305N2

Enrollment

Registered

2020-12-01

Start date

2014-04-04

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle cell anemia. Sickle-cell disorders

Interventions

Intervention group: Administration of Imatinib, made by Osveh, 100mg three times per day , to continue for one year.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: patients with sickle cell syndromes have at least 3 painful crisis or more per year despite adhearence to their standard treatment i.e. hydroxyurea

Exclusion criteria

Exclusion criteria: allergy to imatinib addiction to opiods

Design outcomes

Primary

Measure	Time frame
Number of painful crisis per year in each patient. Timepoint: Before intervention and every 1 month for a year. Method of measurement: Patients self report, Hospitalization record, The amount of analgesic used per month in each patient.;Total number of hospitalization due to painful crisis per year per patient. Timepoint: Before study and then every 1 months for 1 years. Method of measurement: Patients self report, Hospitalization record.	—

Measure

Time frame

Number of painful crisis per year in each patient. Timepoint: Before intervention and every 1 month for a year. Method of measurement: Patients self report, Hospitalization record, The amount of analgesic used per month in each patient.;Total number of hospitalization due to painful crisis per year per patient. Timepoint: Before study and then every 1 months for 1 years. Method of measurement: Patients self report, Hospitalization record.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba Karimi

Shiraz University of Medical Sciences

mjkarimi@sums.ac.ir+98 71 1623 2937

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026